Immune drug studied in thyroid cancer before surgery
NCT ID NCT05852223
First seen May 01, 2026 · Last updated May 25, 2026 · Updated 6 times
Summary
This study tests whether giving the immune-boosting drug pembrolizumab before surgery can help understand how the immune system fights thyroid cancer. About 25 adults with high-risk differentiated thyroid cancer will receive the drug and then have surgery. The main goal is to learn how immune cells change, not to cure the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFERENTIATED THYROID CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Istituti Clinici Scientifici Maugeri
RECRUITINGPavia, Lombardy, 27100, Italy
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.